Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

Petrini I, Lencioni M, Vasile E, Fornaro L, Belluomini L, Pasquini G, Ginocchi L, Caparello C, Musettini G, Vivaldi C, Caponi S, Ricci S, Proietti A, Fontanini G, Naccarato AG, Nardini V, Santi S, Falcone A.

Cancer Biomark. 2018 Feb 14;21(3):731-741. doi: 10.3233/CBM-170865.

PMID:
29278885
2.

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G.

Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: Future Oncol. 2018 Mar;14 (6):577.

PMID:
28976226
3.

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.

Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L.

Oncotarget. 2017 Feb 28;8(9):14408-14415. doi: 10.18632/oncotarget.14797.

4.

Reflections on the national patient-reported outcome measures (PROMs) programme: Where do we go from here?

Kyte D, Cockwell P, Lencioni M, Skrybant M, Hildebrand MV, Price G, Squire K, Webb S, Brookes O, Fanning H, Jones T, Calvert M.

J R Soc Med. 2016 Dec;109(12):441-445. No abstract available.

PMID:
27923896
5.

Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties.

Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee CB, Lane DA.

PLoS One. 2016 Nov 1;11(11):e0165790. doi: 10.1371/journal.pone.0165790. eCollection 2016. Review.

6.

Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.

Pasquini G, Vasile E, Caparello C, Vivaldi C, Musettini G, Lencioni M, Petrini I, Fornaro L, Falcone A.

Oncology. 2016;91(6):311-316. Epub 2016 Oct 6.

PMID:
27705972
7.

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.

Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Weiss A, Miles S, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz BE, Santoro A.

Oncotarget. 2016 Nov 8;7(45):72622-72633. doi: 10.18632/oncotarget.11621.

8.

Minimally Invasive Surgical Technique in Periodontal Regeneration: A Randomized Controlled Clinical Trial Pilot Study.

Ghezzi C, Ferrantino L, Bernardini L, Lencioni M, Masiero S.

Int J Periodontics Restorative Dent. 2016 Jul-Aug;36(4):475-82. doi: 10.11607/prd.2550.

PMID:
27333004
9.

Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.

Giorgetti A, Pallabazzer G, Ripoli A, Solito B, Genovesi D, Lencioni M, Fabrini MG, D'Imporzano S, Pieraccini L, Marzullo P, Santi S.

Medicine (Baltimore). 2016 Mar;95(13):e3151. doi: 10.1097/MD.0000000000003151.

10.

First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.

Vivaldi C, Caparello C, Musettini G, Pasquini G, Catanese S, Fornaro L, Lencioni M, Falcone A, Vasile E.

Int J Cancer. 2016 Aug 15;139(4):938-45. doi: 10.1002/ijc.30125. Epub 2016 Apr 18.

11.

Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.

Caparello C, Vivaldi C, Fornaro L, Musettini G, Pasquini G, Catanese S, Masi G, Lencioni M, Falcone A, Vasile E.

Future Oncol. 2016 Apr;12(7):901-8. doi: 10.2217/fon.16.16. Epub 2016 Feb 17. Review.

PMID:
26883177
12.

Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study.

Umar F, Taylor RJ, Stegemann B, Marshall H, Flannigan S, Lencioni M, De Bono J, Griffith M, Leyva F.

Europace. 2016 Aug;18(8):1227-34. doi: 10.1093/europace/euv396. Epub 2015 Dec 30.

PMID:
26718535
13.

Cardiff cardiac ablation patient-reported outcome measure (C-CAP): validation of a new questionnaire set for patients undergoing catheter ablation for cardiac arrhythmias in the UK.

White J, Withers KL, Lencioni M, Carolan-Rees G, Wilkes AR, Wood KA, Patrick H, Cunningham D, Griffith M.

Qual Life Res. 2016 Jun;25(6):1571-83. doi: 10.1007/s11136-015-1194-1. Epub 2015 Dec 10.

14.

Living on a knife edge-the daily struggle of coping with symptomatic cardiac arrhythmias.

Withers KL, Wood KA, Carolan-Rees G, Patrick H, Lencioni M, Griffith M.

Health Qual Life Outcomes. 2015 Jun 24;13:86. doi: 10.1186/s12955-015-0282-9.

15.

Establishing content validity in a novel patient reported outcome measure for cardiac arrhythmia ablation patients.

Withers KL, Wood KA, Carolan-Rees G, Patrick H, Lencioni M, Griffith M.

Health Qual Life Outcomes. 2015 Mar 20;13:38. doi: 10.1186/s12955-015-0233-5.

16.

Patient reported outcome measures for cardiac ablation procedures: a multicentre pilot to develop a new questionnaire.

Withers KL, White J, Carolan-Rees G, Patrick H, O'Callaghan P, Murray S, Cunningham D, Wood KA, Lencioni M, Griffith M.

Europace. 2014 Nov;16(11):1626-33. doi: 10.1093/europace/euu032. Epub 2014 Mar 13.

17.

Not only chemotherapy in the second-line treatment of metastatic gastric cancer.

Vasile E, Caparello C, Caponi S, Ginocchi L, Vivaldi C, Musettini G, Lucchesi M, Lencioni M, Falcone A.

Ann Oncol. 2014 Feb;25(2):544-5. doi: 10.1093/annonc/mdt570. No abstract available.

PMID:
24478324
18.

Primary retroperitoneal müllerian adenocarcinoma: a case report and literature review.

Spinelli C, Strambi S, Tartaglia D, Di Franco G, Pucci V, Faviana P, Lencioni M.

Case Rep Oncol. 2013 Dec 19;6(3):616-21. doi: 10.1159/000357424. eCollection 2013 Sep.

19.

Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.

Caponi S, Vasile E, Funel N, De Lio N, Campani D, Ginocchi L, Lucchesi M, Caparello C, Lencioni M, Cappelli C, Costa F, Pollina L, Ricci S, Mosca F, Falcone A, Boggi U.

Eur J Surg Oncol. 2013 Apr;39(4):396-403. doi: 10.1016/j.ejso.2012.12.005. Epub 2013 Jan 3.

PMID:
23290583
20.

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C.

Lancet Oncol. 2013 Jan;14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4. Epub 2012 Nov 20.

PMID:
23182627
21.

Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.

Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S.

Cancer Chemother Pharmacol. 2012 Mar;69(3):773-80. doi: 10.1007/s00280-011-1753-2. Epub 2011 Oct 28.

PMID:
22033636
22.

Local activation time derived from stored EGM is associated with failure of antitachycardia pacing in patients with implantable defibrillator.

Lim HS, Lencioni M, Marshall H.

Pacing Clin Electrophysiol. 2010 May;33(5):549-52. doi: 10.1111/j.1540-8159.2009.02638.x. Epub 2009 Dec 10.

PMID:
20015127
23.

A single-institutional brachytherapy experience in the management of esophageal cancer.

Fabrini MG, Perrone F, De Liguoro M, Coppola M, Santi S, Solito B, Lencioni M, Rossi M, Cionini L.

Brachytherapy. 2010 Apr-Jun;9(2):185-91. doi: 10.1016/j.brachy.2009.08.006. Epub 2009 Oct 28.

PMID:
19875341
24.

5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.

Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R.

Clin Cancer Res. 2008 May 1;14(9):2749-55. doi: 10.1158/1078-0432.CCR-07-1529.

25.

Verification of electrical isolation of pulmonary veins following left atrial circumferential ablation may require sinus rhythm.

Lencioni M, Muhyaldeen S, Marshall H, Griffith M.

Europace. 2008 May;10(5):606-8. doi: 10.1093/europace/eun074. Epub 2008 Apr 9.

PMID:
18403389
26.

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF.

Br J Cancer. 2005 Jul 11;93(1):35-40.

27.

Coronary endarterectomy: impact on morbidity and mortality when combined with coronary artery bypass surgery.

Tiruvoipati R, Loubani M, Lencioni M, Ghosh S, Jones PW, Patel RL.

Ann Thorac Surg. 2005 Jun;79(6):1999-2003.

PMID:
15919299
28.

5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.

Allegrini G, Falcone A, Di Marsico R, Lencioni M, Masi G, Galli C, Cupini S, Pfanner E, Marcucci L, Conte PF.

Am J Clin Oncol. 2004 Feb;27(1):101-5.

PMID:
14758142
29.

Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.

Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P.

J Clin Oncol. 2001 Aug 1;19(15):3456-62.

PMID:
11481350
30.

5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.

Falcone A, Allegrini G, Masi G, Lencioni M, Pfanner E, Brunetti I, Danesi R, Bocci G, Del Tacca M, Conte P.

Oncology. 2001;61(1):28-35.

PMID:
11474245
31.

Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.

Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I, Di Marsico R, Fontana E, Orlandini C, Stampino CG, Bartolozzi C, Conte PF.

Oncology. 2000 Sep;59(3):204-9.

PMID:
11053987
32.

Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery.

Falcone A, Allegrini G, Antonuzzo A, Brunetti I, Pfanner E, Lencioni M, Masi G, Danesi R, Del Tacca M, Conte P.

Oncology. 1999 Oct;57(3):195-201.

PMID:
10545787
33.

Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.

Falcone A, Allegrini G, Lencioni M, Pfanner E, Brunetti I, Cianci C, Galli C, Masi G, Antonuzzo A, Conte P.

Cancer Chemother Pharmacol. 1999;44(2):159-63.

PMID:
10412951
34.

Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.

Falcone A, Pfanner E, Brunetti I, Allegrini G, Lencioni M, Galli C, Masi G, Danesi R, Antonuzzo A, Del Tacca M, Conte PF.

Tumori. 1998 Nov-Dec;84(6):666-8.

PMID:
10080673
36.

Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.

Baldini E, Tibaldi C, Lencioni M, Giannessi P, Evangelista G, Roncella M, Spinelli C, Meucci C, da Prato M, Conte P.

Am J Clin Oncol. 1997 Apr;20(2):169-72.

PMID:
9124194
37.

Postoperative adjuvant chemoradiotherapy for rectal cancer: analysis of acute and chronic toxicity.

Bertuccelli M, Cartei F, Falcone A, Campoccia S, Sainato A, Ducci F, Moda S, Pfanner E, Lencioni M, Brunetti I, Giulianotti PC, Mosca F, Laddaga M, Conte PF.

Tumori. 1997 Mar-Apr;83(2):599-603.

PMID:
9226028
38.

Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience.

Lencioni R, Pinto F, Armillotta N, Bassi AM, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, Bartolozzi C.

Eur Radiol. 1997;7(4):514-9.

PMID:
9204330
39.

Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.

Falcone A, Cianci C, Pfanner E, Ricci S, Lencioni M, Brunetti I, Giulianotti PC, Vannucci L, Mosca F, Conte PF.

Ann Oncol. 1996 Aug;7(6):601-5.

PMID:
8879374
40.

Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria.

Heller PG, Grinberg AR, Lencioni M, Molina MM, Roncoroni AJ.

Chest. 1992 Aug;102(2):642-3.

PMID:
1643968

Supplemental Content

Loading ...
Support Center